BR112014024255A2 - Derivados de heteroarila bicíclica como moduladores de mnk1 e mnk2 e a utilização dos mesmos - Google Patents

Derivados de heteroarila bicíclica como moduladores de mnk1 e mnk2 e a utilização dos mesmos

Info

Publication number
BR112014024255A2
BR112014024255A2 BR112014024255A BR112014024255A BR112014024255A2 BR 112014024255 A2 BR112014024255 A2 BR 112014024255A2 BR 112014024255 A BR112014024255 A BR 112014024255A BR 112014024255 A BR112014024255 A BR 112014024255A BR 112014024255 A2 BR112014024255 A2 BR 112014024255A2
Authority
BR
Brazil
Prior art keywords
mnk2
mnk1
modulators
bicyclic heteroaryl
heteroaryl derivatives
Prior art date
Application number
BR112014024255A
Other languages
English (en)
Other versions
BR112014024255B1 (pt
Inventor
Kassoum Nacro
Athisayamani Jeyaraj Duraiswamy
Lohitha Rao Chennamaneni
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Publication of BR112014024255A2 publication Critical patent/BR112014024255A2/pt
Publication of BR112014024255B1 publication Critical patent/BR112014024255B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112014024255-0A 2012-03-30 2013-04-01 Derivados de heteroarila bicíclica como moduladores de mnk1 e mnk2 e a utilização dos mesmos BR112014024255B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1205669.3 2012-03-30
GBGB1205669.3A GB201205669D0 (en) 2012-03-30 2012-03-30 Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
PCT/SG2013/000126 WO2013147711A1 (en) 2012-03-30 2013-04-01 Bicyclic heterocyclic derivatives as mnk1 and mnk2 modulators and uses thereof

Publications (2)

Publication Number Publication Date
BR112014024255A2 true BR112014024255A2 (pt) 2017-06-20
BR112014024255B1 BR112014024255B1 (pt) 2021-12-28

Family

ID=46160013

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014024255-0A BR112014024255B1 (pt) 2012-03-30 2013-04-01 Derivados de heteroarila bicíclica como moduladores de mnk1 e mnk2 e a utilização dos mesmos

Country Status (14)

Country Link
US (3) US9908886B2 (pt)
EP (2) EP2831079B1 (pt)
JP (2) JP6475158B2 (pt)
KR (1) KR102153320B1 (pt)
CN (1) CN104350055B (pt)
AU (2) AU2013240612B2 (pt)
BR (1) BR112014024255B1 (pt)
DK (1) DK2831079T3 (pt)
ES (1) ES2647959T3 (pt)
GB (1) GB201205669D0 (pt)
NO (1) NO2831079T3 (pt)
PL (1) PL2831079T3 (pt)
SG (2) SG11201406207PA (pt)
WO (1) WO2013147711A1 (pt)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013142817A2 (en) 2012-03-23 2013-09-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
US10280168B2 (en) 2012-03-30 2019-05-07 Agency For Science, Technology And Research Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
TWI574962B (zh) 2012-11-14 2017-03-21 加拓科學公司 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途
WO2014130375A1 (en) 2013-02-21 2014-08-28 Calitor Sciences, Llc Heteroaromatic compounds as pi3 kinase modulators
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
WO2014151630A2 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
AR097543A1 (es) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
TW201542550A (zh) * 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法
GB2518873A (en) * 2013-10-03 2015-04-08 Agency Science Tech & Res Bicyclic alkyne derivatives and uses thereof
BR112016012243A2 (pt) * 2013-12-09 2017-08-08 Ucb Biopharma Sprl Derivados de imidazopiridina como moduladores de atividade de tnf
HUE040254T2 (hu) 2013-12-19 2019-02-28 Novartis Ag Protozoa proteaszóma inhibitor [1,2,4]triazolo[1,5-a]pirimidinszármazékok paraziták által okozott betegségek, például leishmaniasis kezelésére
US9944648B2 (en) * 2014-01-09 2018-04-17 Intra-Cellular Therapies, Inc. Organic compounds
RS65417B1 (sr) 2014-01-24 2024-05-31 Turning Point Therapeutics Inc Diaril makrocikli kao modulatori protein kinaza
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US9670210B2 (en) 2014-02-13 2017-06-06 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
TWI720451B (zh) 2014-02-13 2021-03-01 美商英塞特控股公司 作為lsd1抑制劑之環丙胺
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
EA201792205A1 (ru) 2015-04-03 2018-02-28 Инсайт Корпорейшн Гетероциклические соединения как ингибиторы lsd1
KR20180004740A (ko) 2015-04-20 2018-01-12 이펙터 테라퓨틱스, 인크. 암 및 감염 치료에 사용하기 위한 면역 체크포인트 조절 인자의 억제제
AU2016255434C1 (en) * 2015-04-29 2021-09-23 Rapport Therapeutics, Inc. Azabenzimidazoles and their use as AMPA receptor modulators
ES2821049T3 (es) 2015-06-18 2021-04-23 89Bio Ltd Derivados de piperidina 1,4 sustituidos
JP6986972B2 (ja) 2015-06-18 2021-12-22 エイティナイン バイオ リミテッド 置換４−ベンジル及び４−ベンゾイルピペリジン誘導体
WO2017004342A1 (en) 2015-07-02 2017-01-05 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
CN108026108B (zh) 2015-07-06 2021-06-22 特普医药公司 二芳基大环多晶型物
DK3325488T3 (da) 2015-07-21 2020-09-14 Turning Point Therapeutics Inc Chiral diaryl-makrocyklus og anvendelse deraf til behandling af cancer
AU2016306555B2 (en) 2015-08-12 2021-01-28 Incyte Holdings Corporation Salts of an LSD1 inhibitor
WO2017040993A1 (en) * 2015-09-03 2017-03-09 The Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of dyrk1a and uses thereof
MX2018004879A (es) * 2015-10-22 2019-02-28 Selvita S A Nuevos derivados de piridona y su uso como inhibidores de quinasas.
US10851082B2 (en) 2015-10-28 2020-12-01 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)
AU2016343980A1 (en) * 2015-10-29 2018-06-07 Effector Therapeutics, Inc. Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit Mnk1 and Mnk2
KR20180070695A (ko) 2015-10-29 2018-06-26 이펙터 테라퓨틱스, 인크. Mnk1 및 mnk2의 이소인돌린, 아자이소인돌린, 디히드로인데논 및 디히드로아자인데논 억제제
WO2017087808A1 (en) 2015-11-20 2017-05-26 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers
EP3397774A1 (en) 2015-12-31 2018-11-07 Effector Therapeutics Inc. Mnk biomarkers and uses thereof
US10166221B2 (en) 2016-04-22 2019-01-01 Incyte Corporation Formulations of an LSD1 inhibitor
WO2018013430A2 (en) * 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection
SG11201900163PA (en) 2016-07-28 2019-02-27 Tp Therapeutics Inc Macrocycle kinase inhibitors
GB201700692D0 (en) * 2017-01-16 2017-03-01 Salvensis Novel compounds and their use in the treatment of schistosomiasis
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
SG11201907356SA (en) 2017-02-14 2019-09-27 Effector Therapeutics Inc Piperidine-substituted mnk inhibitors and methods related thereto
IL271964B1 (en) 2017-07-28 2024-08-01 Turning Point Therapeutics Inc Macrocyclic compounds and their uses
SI3728271T1 (sl) 2017-12-19 2023-01-31 Turning Point Therapeutics, Inc. Makrociklične spojine za zdravljenje bolezni
CN110156786B (zh) * 2018-02-13 2022-06-03 青煜医药研发(上海)有限公司 嘧啶并环化合物及其制备方法和应用
MA51845A (fr) * 2018-02-13 2020-12-23 Shanghai Blueray Biopharma Co Ltd Composé cyclique fusionné à une pyrimidine, son procédé de préparation et son application
EP3564235A1 (en) * 2018-05-03 2019-11-06 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2)
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
CA3118093A1 (en) * 2018-09-28 2020-04-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of dyrk1/clk and uses thereof
EP3870178A4 (en) 2018-10-24 2022-08-03 Effector Therapeutics Inc. CRYSTALLINE FORMS OF MNK INHIBITORS
CN111978325B (zh) * 2019-05-22 2023-11-17 中国药科大学 咪唑并哒嗪类mnk1/mnk2激酶抑制剂及其制备方法和应用
CN111978317A (zh) * 2019-05-22 2020-11-24 上海道熵生物科技有限公司 咪唑并吡啶类mnk1/mnk2激酶抑制剂及其制备方法和应用
CA3148490C (en) * 2019-08-30 2024-04-30 Jae Won Lee Imidazopyridine derivative and pharmaceutical composition comprising same as active ingredient
US20230093480A1 (en) * 2019-12-30 2023-03-23 Devicare SL Compositions for clinical complications associated to devices implanted in the urinary tract
CN112047950B (zh) * 2020-09-14 2023-07-25 华东师范大学 咪唑并吡嗪类衍生物及其合成方法和应用
WO2022053838A1 (en) * 2020-09-14 2022-03-17 The University Of Sussex Small molecule inhibitors of lemur tyrosine kinase 3
US20230000986A1 (en) * 2021-07-01 2023-01-05 Board Of Regents, The University Of Texas System Mnk inhibitors and eif4e phosphorylation modulation to treat inflammatory pain in the aged
WO2023093700A1 (zh) * 2021-11-29 2023-06-01 中国海洋大学 咪唑并噻唑衍生物及其制备方法与应用
CN114113639B (zh) * 2022-01-29 2022-04-19 北京大有天弘科技有限公司 一种血型抗体检测方法及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1746099A1 (en) 2004-12-23 2007-01-24 DeveloGen Aktiengesellschaft Mnk1 or Mnk2 inhibitors
WO2007013673A1 (en) * 2005-07-29 2007-02-01 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
WO2007025090A2 (en) * 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
MX2008011525A (es) 2006-03-09 2008-09-18 Pharmacopeia Inc Inhibidores de mnk2 de 8-heteroarilpurina para el tratamiento de trastornos metabolicos.
AU2007263017A1 (en) 2006-06-22 2007-12-27 Biovitrum Ab (Publ) Pyridine and pyrazine derivatives as MNK kinase inhibitors
US20120058997A1 (en) 2006-11-06 2012-03-08 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
MX2009004700A (es) * 2006-11-06 2009-05-15 Supergen Inc Derivados de imidazo[1,2-b]piridazin y pirazolo[1,5-a] pirimidina y su uso como inhibidores de proteina cinasa.
US8895745B2 (en) 2006-12-22 2014-11-25 Astex Therapeutics Limited Bicyclic heterocyclic compounds as FGFR inhibitors
AR067326A1 (es) 2007-05-11 2009-10-07 Novartis Ag Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
WO2009050183A2 (en) * 2007-10-17 2009-04-23 Novartis Ag Imidazo [1, 2-a] pyridine derivatives useful as alk inhibitors
WO2010055072A2 (en) 2008-11-12 2010-05-20 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating a mnk
TW201107329A (en) * 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
NZ598220A (en) * 2009-08-17 2014-02-28 Intellikine Llc Heterocyclic compounds and uses thereof
UY33241A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
AU2011246067A1 (en) * 2010-04-28 2012-09-27 Daiichi Sankyo Company, Limited [5,6] heterocyclic compound
ES2539257T3 (es) * 2010-07-28 2015-06-29 Bayer Intellectual Property Gmbh Imidazo[1,2-b]piridazinas sustituidas
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
US10280168B2 (en) 2012-03-30 2019-05-07 Agency For Science, Technology And Research Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
CN105431148A (zh) * 2013-03-07 2016-03-23 加利菲亚生物公司 混合谱系激酶抑制剂及治疗方法

Also Published As

Publication number Publication date
US20180208600A1 (en) 2018-07-26
JP2019031560A (ja) 2019-02-28
PL2831079T3 (pl) 2018-01-31
CN104350055A (zh) 2015-02-11
DK2831079T3 (da) 2017-11-27
SG10201706594PA (en) 2017-09-28
US20140371199A1 (en) 2014-12-18
GB201205669D0 (en) 2012-05-16
AU2017219039A1 (en) 2017-09-14
JP6662984B2 (ja) 2020-03-11
WO2013147711A1 (en) 2013-10-03
AU2013240612B2 (en) 2017-05-25
US9908886B2 (en) 2018-03-06
EP3321268A1 (en) 2018-05-16
KR20150002639A (ko) 2015-01-07
EP2831079A1 (en) 2015-02-04
BR112014024255B1 (pt) 2021-12-28
JP6475158B2 (ja) 2019-02-27
CN104350055B (zh) 2019-05-31
KR102153320B1 (ko) 2020-09-08
SG11201406207PA (en) 2014-11-27
AU2013240612A1 (en) 2014-10-16
EP2831079A4 (en) 2015-11-18
JP2015511638A (ja) 2015-04-20
NO2831079T3 (pt) 2018-01-13
ES2647959T3 (es) 2017-12-27
US11040978B2 (en) 2021-06-22
US20190315755A1 (en) 2019-10-17
EP2831079B1 (en) 2017-08-16

Similar Documents

Publication Publication Date Title
BR112014024255A2 (pt) Derivados de heteroarila bicíclica como moduladores de mnk1 e mnk2 e a utilização dos mesmos
CL2015001321A1 (es) Anticuerpos anti-ceacam5 y usos de éstos
CO7051028A2 (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
BR112014030917A2 (pt) artigo absorvente
BR112015000675A2 (pt) derivados de imidazopiridina como moduladores da atividade de tnf
BR112015000581A2 (pt) derivados de aril sulfam como moduladores do rorc
DK3536310T3 (da) Sprøjte
DK3656373T3 (da) Sprøjte
BR302013001785S1 (pt) Configuração aplicada em banda de rodagem de pneumático
AR092198A1 (es) Derivados de pirazolopirimidinas
BR302013001786S1 (pt) Configuração aplicada em banda de rodagem de pneumático
CO6990717A2 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
BR112014026835A2 (pt) artigo absorvente
SG11201503535PA (en) Hollow hydrogel capsules and methods of using the same
BR112015014598A2 (pt) artigo absorvente
CO7020919A2 (es) Derivados de tetrahidro-quinazolinona
BR112015002636A2 (pt) produto absorvente descartável com fixação adessiva temporária e métodos relacionados
BR112014026553A2 (pt) Fralda descartável
DE112012005631T8 (de) Grossflächige DVPN-Vernetzung und Spoke Hintergrund
BR112014015298A8 (pt) derivados de aza-adamantano e usos dos mesmos
BR112016008387A2 (pt) Conjunto de absorvente descartável, e, artigo absorvente
FR2987600B1 (fr) Nacelle aplatie de turboreacteur
CO7020916A2 (es) Utilizacion en terapeutica de derivados de imidazopiridina
BR302013001613S1 (pt) Configuração aplicada em banda de rodagem de pneumático
DK2820042T3 (da) Igg-stimuleret remyelinisering af perifere nerver

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/04/2013, OBSERVADAS AS CONDICOES LEGAIS.